In this eBook, we explore the pros and cons of emerging and traditional proteomics technologies in terms of coverage and detail.
Data indicate that the AutoCell platform could pave the way for CGTs for the first time as first-line therapies.
The field of cancer immunology has witnessed dramatic progress with the advent of immunotherapies targeting the tumor immune microenvironment (TIME).
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback